专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100028330A1 METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES 有权
标题翻译：使用抗PD1抗体进行适应性免疫应答的方法
公开(公告)号：US20100028330A1
公开(公告)日：2010-02-04
申请号：US12405058
申请日：2009-03-16
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia-Valge Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia-Valge Archer , John Andrews , Caroline Russell
IPC分类号： A61K39/395 , C07K16/18 , C07H21/00 , C12N15/74 , C12N5/07 , C12P21/00 , A61P37/04
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

2. 发明授权

US07521051B2 Methods of upmodulating adaptive immune response using anti-PD-1 antibodies 失效
标题翻译：使用抗PD-1抗体上调适应性免疫应答的方法
公开(公告)号：US07521051B2
公开(公告)日：2009-04-21
申请号：US10540084
申请日：2003-12-22
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
IPC分类号： A61K39/395
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

3. 发明申请

US20080311117A1 Antibodies against PD-1 and uses therefor 审中-公开
标题翻译：抗PD-1抗体及其用途
公开(公告)号：US20080311117A1
公开(公告)日：2008-12-18
申请号：US11893989
申请日：2007-08-17
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

4. 发明授权

US08088905B2 Nucleic acids encoding antibodies against PD-1 有权
标题翻译：编码抗PD-1抗体的核酸
公开(公告)号：US08088905B2
公开(公告)日：2012-01-03
申请号：US12405058
申请日：2009-03-16
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
IPC分类号： C12N15/11
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

5. 发明授权

US07488802B2 Antibodies against PD-1 失效
标题翻译：抗PD-1抗体
公开(公告)号：US07488802B2
公开(公告)日：2009-02-10
申请号：US10741481
申请日：2003-12-22
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Vila Valge-Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Vila Valge-Archer , John Andrews , Caroline Russell
IPC分类号： C07K16/00 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可以用于例如治疗自身免疫疾病，炎性疾病，过敏，移植排斥，癌症和其他免疫系统疾病。

6. 发明申请

US20060210567A1 Antibodies against pd-1 and uses therefor 失效
标题翻译：针对pd-1的抗体及其用途
公开(公告)号：US20060210567A1
公开(公告)日：2006-09-21
申请号：US10540084
申请日：2003-12-22
申请人： Mary Collins , Clive Wood , Beatriz Carreno , Deborah Luxenberg , Jason Jussif , Laura Carter , Frances Bennett , Viia-Valge Archer , Caroline Russell
发明人： Mary Collins , Clive Wood , Beatriz Carreno , Deborah Luxenberg , Jason Jussif , Laura Carter , Frances Bennett , Viia-Valge Archer , Caroline Russell
IPC分类号： A61K39/395 , C07K16/40 , C07H21/04 , C12P21/06 , C12N1/21 , C12N5/06
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

7. 发明申请

US20080241130A1 METHODS AND COMPOSITIONS FOR MODULATING IL-17F/IL-17A BIOLOGICAL ACTIVITY 审中-公开
公开(公告)号：US20080241130A1
公开(公告)日：2008-10-02
申请号：US12057778
申请日：2008-03-28
申请人： Jill F. Wright , Spencer C. Liang , Frances K. Bennett , Mary Collins , Beatriz M. Carreno
发明人： Jill F. Wright , Spencer C. Liang , Frances K. Bennett , Mary Collins , Beatriz M. Carreno
IPC分类号： A61K39/395 , G01N33/557 , A61K38/17 , A61P11/06
CPC分类号： G01N33/6869 , G01N2333/54 , G01N2500/02
摘要： The invention provides a novel mouse IL-17F/IL-17A, and further provides uses of such mouse IL-17F/IL-17A in the characterization of the IL-17F/IL-17A heterodimer. The present invention is also related to polynucleotides and polypeptides of the IL-17F/IL-17A signaling pathway, and targeting of the IL-17F/IL-17A signaling pathway in methods of treating IL-17F/IL-17A-associated disorders. The invention thus provides methods of using isolated IL-17F/IL-17A heterodimer, e.g., in a mouse model of airway inflammation, and specific or selective IL-17F/IL-17A modulators (e.g., signaling agonists or signaling antagonists (e.g., specific or selective antagonistic antibodies, specific or selective antagonistic small molecules, etc.)). The invention also provides methods of screening for compounds capable of modulating IL-17F/IL-17A biological activity, e.g., IL-17F/IL-17A signaling antagonists (e.g., using the mouse model of airway inflammation), as well as methods of identifying whether the IL-17F/IL-17A modulator is a specific IL-17F/IL-17A modulator. The invention is also directed to novel methods for diagnosing, prognosing, monitoring, preventing, and/or treating IL-17F/IL-17A-associated disorders, including, but not limited to, inflammatory disorders (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., airway inflammation, chronic obstructive pulmonary disease, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets identified by methods of screening of the invention, and uses of such identified therapeutics in methods of treatment and prevention of IL-17F/IL-17A-associated disorders.

8. 发明授权

US08143385B2 Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor 失效
标题翻译：编码针对人IL-21受体的抗体的核酸并用于其
公开(公告)号：US08143385B2
公开(公告)日：2012-03-27
申请号：US12353812
申请日：2009-01-14
申请人： Viia Valge-Archer , Andrew James Williams , Deborah A. Young , Matthew J. Whitters , Mary Collins , Joann Witek
发明人： Viia Valge-Archer , Andrew James Williams , Deborah A. Young , Matthew J. Whitters , Mary Collins , Joann Witek
IPC分类号： C07H21/04 , A61K39/00 , C12N5/16 , H01N33/53
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/56 , C07K2317/622
摘要： The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本申请提供了特异性结合人白细胞介素-21受体（IL-21R）的人抗体及其抗原结合片段。抗体可以作为IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。所公开的组合物和方法可用于例如诊断，治疗或预防炎性疾病，自身免疫疾病，过敏，移植排斥，癌症和其他免疫系统疾病。

9. 发明申请

US20100297151A1 ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR 失效
标题翻译：抗人IL-21受体的抗体及其用途
公开(公告)号：US20100297151A1
公开(公告)日：2010-11-25
申请号：US12353812
申请日：2009-01-14
申请人： Viia Valge-Archer , Andrew James Williams , Deborah A. Young , Matthew J. Whitters , Mary Collins , Joann Witek
发明人： Viia Valge-Archer , Andrew James Williams , Deborah A. Young , Matthew J. Whitters , Mary Collins , Joann Witek
IPC分类号： A61K39/395 , C07K16/28 , C07K16/00 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/21 , C12N1/19 , C12P21/02 , C12N5/07 , A61P29/00 , A61P37/02 , A61P17/06 , A61P1/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/56 , C07K2317/622
摘要： The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本申请提供了特异性结合人白细胞介素-21受体（IL-21R）的人抗体及其抗原结合片段。抗体可以作为IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。所公开的组合物和方法可用于例如诊断，治疗或预防炎性疾病，自身免疫疾病，过敏，移植排斥，癌症和其他免疫系统疾病。

10. 发明授权

US07495085B2 Antibodies against human or mouse IL-21 receptor 失效
标题翻译：针对人或小鼠IL-21受体的抗体
公开(公告)号：US07495085B2
公开(公告)日：2009-02-24
申请号：US10798380
申请日：2004-03-12
申请人： Viia Valge-Archer , Andrew James Williams , Deborah A. Young , Matthew J. Whitters , Mary Collins , Joann Witek
发明人： Viia Valge-Archer , Andrew James Williams , Deborah A. Young , Matthew J. Whitters , Mary Collins , Joann Witek
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , C12P21/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/56 , C07K2317/622
摘要： The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本申请提供了特异性结合人白细胞介素-21受体（IL-21R）的人抗体及其抗原结合片段。抗体可以作为IL-21R活性的拮抗剂，从而调节一般的免疫应答，特别是由IL-21R介导的那些。所公开的组合物和方法可用于例如诊断，治疗或预防炎性疾病，自身免疫疾病，过敏，移植排斥，癌症和其他免疫系统疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式